VIRIDIAN THERAPEUTICS INC

NASDAQ: VRDN (Viridian Therapeutics, Inc.)

Kemas kini terakhir: 17 jam lalu

29.84

0.04 (0.13%)

Penutupan Terdahulu 29.80
Jumlah Dagangan 1,147,715
Harga / Jualan (P/S) 122.57
Harga / Buku (P/B) 7.26
Julat 52 Minggu
13.18 (-55%) — 34.29 (14%)
Margin Operasi (TTM) -130,369.45%
EPS Cair (TTM) -3.35
Jumlah Hutang/Ekuiti (D/E MRQ) 3.82%
Nisbah Semasa (MRQ) 19.49
Aliran Tunai Operasi (OCF TTM) -279.75 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -171.41 M
Pulangan Atas Aset (ROA TTM) -32.62%
Pulangan Atas Ekuiti (ROE TTM) -51.95%

AISkor Stockmoo

0.9
Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info NA
Penilaian Relatif info NA
Pertumbuhan Tersirat info NA
Sejarah Penilaian info NA
Hutang rendah. Keuntungan lemah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info
Pulangan di bawah kos modalnya. Pulangan atas modal meningkat. info
Daripada analisis teknikal AI kami terhadap carta. info NA
Aliran menurun sepanjang tahun lalu. Agak di bawah paras tertinggi 52 minggu. info
Harga dan purata bergeraknya tersusun dalam aliran menaik. Purata bergerak utamanya sedang meningkat. Hampir dengan purata bergerak yang meningkat. Dagangan lebih tinggi pada hari harga naik. info
Corak Lilin info NA
Di atas garis aliran jangka sederhana. info
Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info
Berita terkini kebanyakannya positif. info
Aktiviti Orang Dalam info NA
Institusi bersih +3.87% daripada saham dalam pemfailan 13F terkini: 136 pemegang menambah, 88 mengurang (suku berakhir 30 Sep 2026). info
Kedudukan jual singkat -12.7% dari 31 Aug hingga 30 Oct 2026, 9.1 hari untuk tutup (FINRA). info
Persekitaran pasaran berhati-hati. info
Sektor ketinggalan berbanding pasaran.
Tonggak-tonggak sependapat, jadi skor diperkukuh.
Harga tinggi berbanding purata 52 minggunya. Naik dalam tempoh 5 tahun. info
Aliran naik bagi ketiga-tiga tempoh. Momentum jangka pendek meningkat. info
Harga hampir dengan paras rintangan. info
Skor Akhir 0.87
Tunjuk semua

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Menaik
Biotechnology (Global) Bercampur Menaik
Stok Viridian Therapeutics, Inc. Bercampur Menaik

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
VRDN - - - 7.26
TRML 1 B - - 4.76
OBIO - - - 57.25
VRCA - - - 15.60
TECH - 0.44% - 5.28
ABEO - - - 1.10

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Core
% Dimiliki oleh Orang Dalam 0.16%
% Dimiliki oleh Institusi 114.61%

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

Institusi

Pemilikan institusi: 126.23%

Kedudukan Pemegang Saham
Bertambah 136 20,191,430
Berkurang 88 17,420,004
Baharu 45 7,039,728
Dijual habis 25 5,397,253

Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.

Kedudukan Jual Singkat

Penyelesaian Saham Hari untuk tutup
30 Oct 2026 17,042,236 9.1
15 Oct 2026 18,002,311 8.0
30 Sep 2026 17,965,668 8.9
15 Sep 2026 19,465,251 15.7
31 Aug 2026 19,511,841 16.6
14 Aug 2026 19,026,492 9.1

Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.

8 Positif 1 Negatif 3 Neutral
Tarikh Jenis Butiran
09 Nov 2026 Yahoo Finance Viridian Therapeutics gains long-term potential from extended-acting FcRn drug, Jefferies says
Jefferies sees VRDN-008 as a potential best-in-class FcRn inhibitor, with its extended half-life supporting eight-week dosing and offering a competitive advantage in a market dominated by less convenient treatment schedules. The broker views Viridian Therapeutics (NASDAQ:VRDN)'s decision to…
09 Nov 2026 Yahoo Finance Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing
WALTHAM, Mass., November 09, 2026--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced positive phase 1 results for VRDN-008…
07 Nov 2026 Yahoo Finance Viridian Therapeutics Inc (VRDN) (Q3 2026) Earnings Call Highlights: Lumvoa's Strong Debut With ...
Viridian Therapeutics Inc (VRDN) kicked off its Lumvoa launch with more than 100 patients treated and over $955 million in cash to fund operations through profitability.
06 Nov 2026 Yahoo Finance Viridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026
WALTHAM, Mass., November 06, 2026--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced it will host a conference call and webcast to present…
06 Nov 2026 Yahoo Finance Wall Street Analysts Predict a 39.68% Upside in Viridian Therapeutics (VRDN): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 39.7% in Viridian Therapeutics (VRDN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
04 Nov 2026 Yahoo Finance Viridian Therapeutics, Inc. Q3 2026 Earnings Call Summary
Moby summary of Viridian Therapeutics, Inc.'s Q3 2026 earnings call…
04 Nov 2026 Yahoo Finance Viridian Therapeutics (VRDN) Stock Looks Overvalued Even With Its New Launch
Viridian Therapeutics has had a powerful three year run, yet the real puzzle for investors is whether the current share price still lines up with what its balance sheet supports. With fresh product launches and pipeline progress now in the mix, the question is how far the stock has moved relative…
04 Nov 2026 Yahoo Finance What Viridian Therapeutics (VRDN) Said on Its Q3 Earnings Call
Viridian Therapeutics (NASDAQ:VRDN) reported $24.7 million in net product revenue from Lumvoa in the thyroid eye disease treatment’s first quarter on the market, with more than 100 patients having received at least one infusion by Sept. 30. President and CEO Steve Mahoney said the launch exceeded t…
04 Nov 2026 Yahoo Finance Viridian (VRDN) Q3 2026 Earnings Call Transcript
First full quarter of Lumvoa sales beat expectations as patient starts accelerated.
04 Nov 2026 Yahoo Finance Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Beats Revenue Estimates
Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of +19.80% and +348.17%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
04 Nov 2026 Yahoo Finance Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress
WALTHAM, Mass., November 04, 2026--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported financial results and recent business updates for the…
02 Nov 2026 Yahoo Finance A $2 Billion Fund Bought These 3 Stocks Last Quarter
Key TakeawaysA $2 billion fund’s latest 13F shows its three biggest adds in the quarter ended June 30 were Viridian Therapeutics, Travere Therapeutics, and Legend Biotech. Analysts’ average price targets sit 47% to 111% above Friday’s close for the three stocks.
27 Oct 2026 Yahoo Finance How FDA Approval Will Impact Viridian Therapeutics Stock
Viridian Therapeutics received FDA approval in June 2026 for Lumvoa, an IGF-1R antibody for active and chronic Thyroid Eye Disease, following Phase III data showing meaningful clinical benefits with a 12-week, 5-infusion IV regimen. The approval gives Viridian Therapeutics its first commercial…
20 Oct 2026 Yahoo Finance Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026
WALTHAM, Mass., October 20, 2026--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that it will report third quarter 2026 financial…
16 Oct 2026 Yahoo Finance Viridian Therapeutics (VRDN) Stock May Look Stretched Against Its Sales Base
Viridian Therapeutics has seen a mixed share price story in recent years, which raises a straightforward question for anyone looking at the stock today. Is the current US$19.03 price tag adequately grounded in what the company is generating through its sales? Over the past 3 years the stock has…
22 Sep 2026 Yahoo Finance Viridian Therapeutics' Lumvoa Off to 'Stronger Start' Than Anticipated, RBC Says
Viridian Therapeutics' (VRDN) Lumvoa is off to a "stronger start" than anticipated, RBC Capital Mark…
02 Sep 2026 Yahoo Finance Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
WALTHAM, Mass., September 02, 2026--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that senior management will participate in a fireside…
Papar semua

Isyarat Terkini corak lilin dan silang EMA

▲ Silang emas 17 sesi lalu · 23 Oct
Jangka panjang · EMA 50/200
EMA 50 hari melintas ke atas EMA 200 hari, tanda yang diperhatikan ramai bahawa arah aliran jangka panjang telah berubah menaik.

Persediaan Teknikal Sederhana

Susunan aliran
Kecerunan
Kemasukan
Dagangan
Harga dan purata bergeraknya tersusun dalam aliran menaik. Purata bergerak utamanya sedang meningkat. Hampir dengan purata bergerak yang meningkat. Dagangan lebih tinggi pada hari harga naik.
Sokongan terdekat: 29.41 – 31.12 · paras kukuh
Rintangan terdekat: 31.30 – 31.96 · paras sederhana

AI Analisis Teknikal

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda